Izvorni znanstveni članak

SUPEROXIDE DISMUTASE ACTIVITY AND SERUM LIPID PROFILE IN HEMODIALYSIS PATIENTS

AMELA BEĆIRAGIĆ ; Univerzitetski klinički centar Sarajevo, Klinika za hemodijalizu, Sarajevo, Bosna i Hercegovina
HALIMA RESIĆ ; Univerzitetski klinički centar Sarajevo, Klinika za hemodijalizu, Sarajevo, Bosna i Hercegovina
AMELA DERVIŠEVIĆ ; Univerzitet u Sarajevu, Medicinski fakultet, Zavod za humanu fiziologiju, Sarajevo, Bosna i Hercegovina
ALMIR FAJKIĆ ; Univerzitet u Sarajevu, Medicinski fakultet, Zavod za patofiziologiju, Sarajevo, Bosna i Hercegovina
NEJRA PROHIĆ ; Univerzitetski klinički centar Sarajevo, Klinika za hemodijalizu, Sarajevo, Bosna i Hercegovina
NESINA AVDAGIĆ ; Univerzitet u Sarajevu, Medicinski fakultet, Zavod za humanu fiziologiju, Sarajevo, Bosna i Hercegovina
NERMINA BABIĆ ; Univerzitet u Sarajevu, Medicinski fakultet, Zavod za humanu fiziologiju, Sarajevo, Bosna i Hercegovina
SELMA AJANOVIĆ ; Univerzitetski klinički centar Sarajevo, Klinika za hemodijalizu, Sarajevo, Bosna i Hercegovina
AIDA ĆORIĆ ; Univerzitetski klinički centar Sarajevo, Klinika za hemodijalizu, Sarajevo, Bosna i Hercegovina

Sažetak

Objectives/Aim: Hemodialysis (HD) is associated with a number of biochemical abnormalities including dyslipidemia and oxidative stress. The aim of this study was to evaluate the relationship between serum superoxide dismutase (SOD) activity and lipid profi le in HD patients with different duration of HD treatment. Material and Methods: This cross-sectional study included 100 HD patients that were divided into two subgroups based on the duration of HD therapy: patients on HD for more than three months but less than fi ve years (HD <5 years; n=48) and patients on HD for fi ve years or more (HD ≥5 years; n=52). Control group (n=50) consisted of age- and gender-matched, apparently healthy individuals without subjective and objective indicators of any renal disease. Blood samples were obtained for determination of SOD, total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL). Serum SOD concentration was determined by ELISA method using a commercial kit. Results: Serum concentration of SOD was increased in HD patients when compared to healthy controls. SOD concentration was signifi cantly higher in HD <5 year group compared with control group [12.29 (10.85-14.15) vs.11.04 (9.42 -12.99) U/mL; p<0.05]; however, there was no signifi cant difference in SOD concentration between HD≥5 year group [12.97 (10.27-14.56) U/mL] and healthy control subjects. In addition, there was no significant difference in
serum SOD concentration between HD patients with different duration of dialysis therapy. The levels of TC, LDL and HDL were significantly decreased in both groups of HD patients as compared with control subjects (p<0.0005); however, serum TG levels did not differ significantly between the study groups. According to the ROC analysis, serum levels of TC, LDL and HDL had higher sensitivity than serum SOD concentration in differentiating HD patients from healthy subjects. Conclusions: According to our results, it is concluded that increased serum SOD concentration together with alterations in the lipid profi le enhances the risk of atherosclerosis and favors higher incidence of cardiovascular complications in HD patients.

Ključne riječi

hemodialysis; superoxide dismutase; dyslipidemia

Hrčak ID:

208470

URI

https://hrcak.srce.hr/208470

Datum izdavanja:

16.11.2018.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.227 *